|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatoceiluiar carcinoma显示文摘AIM: To explore the potential prognostic role of preoperative tumor grade and blood AFP mRNA in a cohort of patients with hepatocellular carcinoma (HCC)eligible for radical therapies according to a well-defined treatment algorithm not including nodule size and number as absolute selection criteria.METHODS: Fifty patients with a diagnosis of HCC were prospectively enrolled in the study. Inclusion criteria were: (1) histological assessment of tumor grade by means of percutaneous biopsies; (2) determination of AFP mRNA status in the blood; (3) patient's eligibility for radical therapies.RESULTS: At preoperative evaluation, 54% of the study group had a well-differentiated HCC, 42% had AFP mRNA in the blood, 40% had a tumor larger than 5 cm and 56% had more than one nodule. Surgery (resection or liver transplantation) was performed in 29 patients,while 21 had percutaneous ablation procedures. After a median follow-up of 28 mo, 12-, 24-, and 36-mo survival rates were 78%, 58%, and 51%, respectively. Surgical therapy, performance status and three tumor-related variables (AFP mRNA, HCC grade and gross vascular invasion) resulted as significant survival predictors at univariate analysis. Nodule size and number did not perform as significant prognosticators. Multivariate study selected only surgical therapy and a biologically early HCC profile (AFP mRNA negative and well-differentiated tumor without gross vascular invasion) as independent survival variables.CONCLUSION: The preoperative determination of tumor grade and blood AFP mRNA status may potentially refine the prognostic evaluation of HCC patients and improve the selection process for radical therapies. | Umberto Cillo Alessandro Vitale Filippo Navaglia Daniela Basso Umberto Montin Marco Bassanello Francesco D'Amico Francesco Antonio Ciarleglio Alberto Brolese Giacomo Zanus Vito De Pascale Mario Plebani Davide Francesco D'Amico | 2005 | World Journal of Gastroenterology2005，11，44： | 12 |
| 2 | Prediction of hepatocellular carcinoma biological behaviorin patient selection for liver transplantation显示文摘Morphological criteria have always been considered the benchmark for selecting hepatocellular carcinoma(HCC)patients for liver transplantation(LT).These criteria,which are often inappropriate to express the tumor’s biological behavior and aggressiveness,offer only a static view of the disease burden and are frequently unable to correctly stratify the tumor recurrence risk after LT.Alpha-fetoprotein(AFP)and its progression as well as AFP-m RNA,AFP-L3%,des-γ-carboxyprothrombin,inflammatory markers and other serological tests appear to be correlated with post-transplant outcomes.Several other markers for patient selection including functional imaging studies such as18F-FDG-PET imaging,histological evaluation of tumor grade,tissue-specific biomarkers,and molecular signatures have been outlined in the literature.HCC growth rate and response to pre-transplant therapies can further contribute to the transplant evaluation process of HCC patients.While AFP,its progression,and HCC response to pretransplant therapy have already been used as a part of an integrated prognostic model for selecting patients,the utility of other markers in the transplant setting is still under investigation.This article intends to review the data in the literature concerning predictors that could be included in an integrated LT selection model and to evaluate the importance of biological aggressiveness in the evaluation process of these patients. | Umberto Cillo Tommaso Giuliani Marina Polacco Luz Maria Herrero Manley Gino Crivellari Alessandro Vitale | 2016 | World Journal of Gastroenterology2016，22，1： | 7 |
| 3 | Transplant benefit for patients with hepatocellular carcinoma显示文摘Although liver transplantation is theoretically the best treatment for hepatocellular carcinoma(HCC),it is limited by the realities of perioperative complications,and the shortage of donor organs.Furthermore,in many cases there are available alternative treatments such as resection or locoregional therapy.Deciding upon the best option for a patient with HCC is complicated,involving numerous ethical principles including:urgency,utility,intention-to-treat survival,transplant benefit,harm to candidates on waiting list,and harm to living donors.The potential contrast between different principles is particularly relevant for patients with HCC for several reasons:(1)HCC candidates to liver transplantation are increasing;(2)the great prognostic heterogeneity within the HCC population;(3)in HCC patients tumor progression before liver transplantation may significantly impair post transplant outcome;and(4)effective alternative therapies are often available for HCC candidates to liver transplantation.In this paper we suggest that allocating organs by transplant benefit could help balance these competing principles,and also introduce equity between patients with HCC and nonmalignant liver disease.We also propose a triangular equipoise model to help decide between deceased donor liver transplantation,living donor liver transplantation,or alternative therapies. | Alessandro Vitale Michael Volk Umberto Cillo | 2013 | World Journal of Gastroenterology2013，19，48： | 6 |
| 4 | Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study显示文摘 | Alessandro Vitale Patrizia Burra Anna Chiara Frigo Franco Trevisani Fabio Farinati Gaya Spolverato Michael Volk Edoardo G. Giannini Francesca Ciccarese Fabio Piscaglia Gian Lodovico Rapaccini Mariella Di Marco Eugenio Caturelli Marco Zoli Franco Borzio Gi | 2014 | Journal of Hepatology2014，，： | 2 |
| 5 | Molecular Mechanism of the Specificity of Protein Import into Chloroplasts and Mitochondria in Plant Cells显示文摘Plants possess both types of endosymbiotic organelles, chloroplasts and mitochondria. Transit peptides and presequences function as signal sequences for specific import into chloroplasts and mitochondria, respectively. However, how these highly similar signal sequences confer the protein import specificity remains elusive. Here, we show that mitochondrial- or chloroplast-specific import involves two distinct steps, specificity determination and translocation across envelopes, which are mediated by the N-terminal regions and functionally interchangeable C-terminal regions, respectively, of transit peptides and presequences. A domain harboring multiple-arginine and hydrophobic sequence motifs in the N-terminal regions of presequences was identified as the mitochondrial specificity factor. The presence of this domain and the absence of arginine residues in the N-terminal regions of otherwise common targeting signals confers specificity of protein import into mitochondria and chloroplasts, respectively. AtToc159, a chloroplast import receptor, also contributes to determining chloroplast import specificity. We propose that common ancestral sequences were functionalized into mitochondrial- and chloroplast-specific signal sequences by the presence and absence, respectively, of multiple-arginine and hydrophobic sequence motifs in the N-terminal region. | Dong Wook Lee Sumin Lee Junho Lee Seungjin Woo Md.Abdur Razzak Alessandro Vitale Inhwan Hwang | 2019 | Molecular Plant2019，12，7： | 2 |
| 6 | Protein Domains Involved in Assembly in the Endoplasmic Reticulum Promote Vacuolar Delivery when Fused to Secretory GFP, Indicating a Protein Quality Control Pathway for Degradation in the Plant Vacuole显示文摘正确合拢和最新综合的能分泌的蛋白质的汇编被 endoplasmic 蜂窝胃的蛋白质质量控制系统监视(嗯) 。通过和象有约束力的蛋白质(BiP ) 和另外的合拢的助手那样的女伴的相互作用,质量控制赞成为降级有缺陷者蛋白质的高效的合拢和种类。为在酵母,植物,和动物识别的质量控制降级的一条主要线路被 ubiquitin/proteasome 系统,而是选择被 retrotranslocation 从 ER 组成到 cytosol 和随后的处理包含液泡的线路在酵母被识别了。在这研究,我们学习了 sGFP418 的命运,在 GFP 和涉及 phaseolin 的正确汇编并且在 unassembled 子单元的 BiP 识别的 vacuolar 蛋白质 phaseolin 的域的一种能分泌的形式之间的熔化。我们证明尽管有缺乏排序信号的 phaseolin vacuolar, sGFP418 被送到液泡并且碎裂,在被能分泌的交通禁止者 brefeldin A 禁止的一个过程。而且,在 GFP 之间的熔化和涉及玉米朊聚合的玉米存储蛋白质玉米朊的一个领域也经历类似于 sGFP418 的 translational 以后破碎。这些结果证明有通常涉及 oligomerization 的永久地暴露的序列的有缺点的能分泌的蛋白质能被能分泌的交通送到液泡。这强烈建议排序奉献给有缺点的能分泌的蛋白质的处理的机制的植物 vacuolar 的存在。 | Ombretta Foresti Francesca De Marchis Maddalena de Virgilio Eva M. Klein Sergio Arcioni Michele Bellucci Alessandro Vitale | 2008 | Molecular Plant2008，1，6： | 2 |
| 7 | Prospective validation of the Barcelona Clinic Liver Cancer staging system显示文摘 | Umberto Cillo Alessandro Vitale Francesco Grigoletto Fabio Farinati Alberto Brolese Giacomo Zanus Daniele Neri Patrizia Boccagni Nela Srsen Francesco D’Amico Francesco Antonio Ciarleglio Alessio Bridda Davide Francesco D’Amico | 2006 | Journal of Hepatology2006，，4： | 2 |
| 8 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study显示文摘 | Alessandro Vitale Rafael Ramirez Morales Giacomo Zanus Fabio Farinati Patrizia Burra Paolo Angeli Anna Chiara Frigo Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Catur | 2011 | Lancet Oncology2011，，7： | 2 |
| 9 | BCLC staging system and liver transplantation:From a stage to a therapeutic hierarchy显示文摘The Barcelona Clinic Liver Cancer(BCLC)system was proposed in 1999 with the intent to improve a therapeutic algorithm for the management of patients with hepatocellular carcinoma(HCC)[1].Both the European and the American Guidelines on the Treatment of HCC have endorsed the BCLC as the standard staging algorithm with prognostic and therapeutic implications[2,3].The BCLC staging system stratifies HCC patients into five stages(0,A,B,C and D).According to the algorithm,liver transplantation(LT)is indicated only in patients in the stages BCLC 0 and A,special situations provided. | Quirino Lai Alessandro Vitale | 2021 | Hepatobiliary & Pancreatic Diseases International2021，20，1： | 1 |
| 10 | Diabetes Promotes Cardiac Stem Cell Aging and Heart Failure, Which Are Prevented by Deletion of the p66shc Gene显示文摘 | Marcello Rota Nicole LeCapitaine Toru Hosoda Alessandro Boni Antonella De Angelis Maria Elena Padin-Iruegas Grazia Esposito Serena Vitale Konrad Urbanek Claudia Casarsa Marco Giorgio Thomas F. Lüscher Pier Giuseppe Pelicci Piero Anversa Annarosa Leri Jan | 2006 | Circulation Research2006，，1： | 1 |
| 11 | Use of Sorafenib in Patients With Hepatocellular Carcinoma Before Liver Transplantation:A Cost-Benet Analysis While Awaiting Data on Sorafenib Safety显示文摘 | Alessandro Vitale Michael L Volk | 2010 | HEPATOLOGY2010，51，1： | 1 |
| 12 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study显示文摘 | Alessandro Vitale Rafael Ramirez Morales Giacomo Zanus Fabio Farinati Patrizia Burra Paolo Angeli Anna Chiara Frigo Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Catur | 2011 | Lancet Oncology2011，，7： | 1 |
| 13 | Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation显示文摘 | Alessandro Vitale Francesco D’Amico Anna Chiara Frigo Francesco Grigoletto Alberto Brolese Giacomo Zanus Daniele Neri Amedeo Carraro Francesco Enrico D’Amico Patrizia Burra Francesco Russo Paolo Angeli Umberto Cillo | 2010 | Annals of Surgical Oncology2010，，9： | 1 |
| 14 | The survival benefit of liver transplantation in hepatocellular carcinoma patients显示文摘 | Umberto Cillo Alessandro Vitale Michael L. Volk Anna Chiara Frigo Francesco Grigoletto Alberto Brolese Giacomo Zanus Francesco D’Amico Fabio Farinati Patrizia Burra Francesco Russo Paolo Angeli Davide F. D’Amico | 2010 | Digestive and Liver Disease2010，，9： | 1 |
| 15 | Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor显示文摘 | Hideyuki Ikeda Bernard Lethé Frédéric Lehmann Nicolas Van Baren Jean-Fran?ois Baurain Charles De Smet Hervé Chambost Massimo Vitale Alessandro Moretta Thierry Boon Pierre G Coulie | 1997 | Immunity1997，，2： | 1 |
| 16 | Diabetes Promotes Cardiac Stem Cell Aging and Heart Failure, Which Are Prevented by Deletion of the p66shc Gene显示文摘 | Marcello Rota Nicole LeCapitaine Toru Hosoda Alessandro Boni Antonella De Angelis Maria Elena Padin-Iruegas Grazia Esposito Serena Vitale Konrad Urbanek Claudia Casarsa Marco Giorgio Thomas F. Lüscher Pier Giuseppe Pelicci Piero Anversa Annarosa Leri Jan | 2006 | Circulation Research2006，，1： | 1 |
| 17 | Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease显示文摘 | Alessandro Tessitore Fabrizio Esposito Carmine Vitale Gabriella Santangelo Marianna Amboni Antonio Russo Daniele Corbo Giovanni Cirillo Paolo Barone Gioacchino Tedeschi | 2012 | Neurology2012，，23： | 1 |
| 18 | The survival benefit of liver transplantation in hepatocellular carcinoma patients显示文摘 | Umberto Cillo Alessandro Vitale Michael L. Volk Anna Chiara Frigo Francesco Grigoletto Alberto Brolese Giacomo Zanus Francesco D’Amico Fabio Farinati Patrizia Burra Francesco Russo Paolo Angeli Davide F. D’Amico | 2010 | Digestive and Liver Disease2010，，9： | 1 |
| 19 | Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation显示文摘 | Alessandro Vitale Francesco D’Amico Anna Chiara Frigo Francesco Grigoletto Alberto Brolese Giacomo Zanus Daniele Neri Amedeo Carraro Francesco Enrico D’Amico Patrizia Burra Francesco Russo Paolo Angeli Umberto Cillo | 2010 | Annals of Surgical Oncology2010，，9： | 1 |
| 20 | Management of hepatitis C infection before and after liver transplantation显示文摘Chronic hepatitis C(CHC) is the most common indication for liver transplantation(LT). Aggressive treatment of hepatitis C virus(HCV) infection before cirrhosis development or decompensation may reduce LT need and risk of HCV recurrence post-LT. Factors associated with increased HCV risk or severity of recurrence include older age, immunosuppression, HCV genotype 1 and high viral load at LT. HCV recurrence post-LT leads to accelerated liver disease and cirrhosis development with reduced graft and patient survival. Currently, interferon(IFN)-based regimens can be used in dualagent regimens with ribavirin, in triple-agent antiviral strategies with direct-acting antivirals(e.g., protease inhibitors telaprevir or boceprevir), or before transplant in compensated patients to reduce HCV viral load to prevent or reduce the risk of post-LT recurrence and complications; they cannot be used in patients with decompensated cirrhosis. IFN-based regimens are used in less than half of HCV-infected patients waiting for LT due to extremely low efficacy and poor tolerability. However, antiviral therapy is indicated after LT in patients with histologically confirmed CHC despite tolerability issues. Improvements in side effect management have increased survival in patients achieving therapeutic targets. HCV treatment pre- and post-LT results in significant health care costs especially when lack of efficacy leads to disease worsening, although studies have shown sofosbuvir treatment before LT vs conventional post-LT dual antiviral is cost effective. The suboptimal efficacy and tolerability of IFN-based therapies, plus the significant economic burden, means the need for effective and well tolerated IFN-free antiHCV therapy for pre- and post-LT remains high. | Stefano Fagiuoli Roberto Ravasio Maria Grazia Lucà Anna Baldan Silvia Pecere Alessandro Vitale Luisa Pasulo | 2015 | World Journal of Gastroenterology2015，21，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员